Engflag

Hylosept

Quick links to important sections

Hylosept

Hylosept_EN

Method of action: Antibacterial Local, Antibiotics And Chemotherapeutics For Dermatological Use, Bacteriostatic, Ophthalmologicals

Treatment option: Abscess, Blepharitis, Gonorrhea, Dermatitis, Dermatitis,Contact, Impetigo, Infection, Infection,Skin, Keratitis, Paronychia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hylosept

Hylosept is a medicinal product defined by its sole active ingredient, Fusidic Acid, which is also frequently available as its salt form, sodium fusidate.

Property Description
Active ingredient Fusidic Acid (sodium fusidate)
Form Cream, ointment, eye drops, tablets, injection
Pharmacological class Fusidanes (Steroid Antibiotic)
Common use Arresting bacterial proliferation
Origin Naturally derived (from Fusidium coccineum)

Fusidic Acid: Identity and Unique Classification

Fusidic Acid is primarily categorized as an antibiotic, but its structure places it in the distinct class known as the fusidanes. It is a naturally derived compound initially isolated from the fungus Fusidium coccineum. This unique chemical structure, which is tetracyclic, leads to its formal classification as a steroid antibiotic, though it contains no actual corticosteroid properties. It possesses specialized activity against susceptible Gram-positive bacteria, particularly the Staphylococcus genus, which is associated with common skin infections.

Available Forms and General Therapeutic Purpose

Hylosept's active ingredient is supplied in various pharmaceutical preparations to enable both topical (localized) and systemic (internal) application. The medicine is commonly available as a cream or ointment for cutaneous use on the skin, and as eye drops for ophthalmic application. Additionally, oral tablets and solutions for intravenous injection are manufactured for systemic treatment. Regardless of the form, the general therapeutic purpose of Hylosept is to provide targeted antimicrobial action that arrests the proliferation of pathogens. This bacteriostatic effect is utilized to limit the spread of bacteria, thereby allowing the body’s natural immune system to effectively contain and resolve the existing bacterial challenge.

What side effects are possible with Hylosept?

Possible side effects and safety information

The officially documented adverse reactions for Hylosept (Fusidic Acid) are categorized by frequency and the body system affected, distinguishing between systemic (oral/injection) and topical (cream/eye drops) use, as defined in regulatory labeling.

Common and Uncommon Adverse Reactions

For systemic use, Common adverse reactions documented include diarrhoea and vomiting, alongside general effects like fatigue or asthenia. Uncommon effects include abnormal liver function tests, jaundice, and various skin reactions like pruritus or rash. For topical forms, uncommon effects are primarily local, such as application site irritation or different forms of dermatitis.

Serious Adverse Reactions and Constraints

Rare but serious adverse reactions documented in official labeling include severe liver issues, such as hepatic failure, and serious, potentially life-threatening skin conditions like DRESS syndrome and Stevens-Johnson syndrome (SJS), which typically appear in the first weeks of therapy. Hypersensitivity to fusidic acid is a formal contraindication.

Population and Interaction-Related Safety

Specific caution is advised regarding systemic co-administration with statins (e.g., simvastatin), as this combination is restricted due to the established risk of severe rhabdomyolysis. Special considerations also apply to neonates, where caution is advised due to the theoretical risk of kernicterus, and for patients with hepatic impairment, who require liver function monitoring as documented in official prescribing information. Additionally, extended or recurrent use is associated with an increased risk of developing antibiotic resistance.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information addresses the risk of an overdose with Hylosept (trastuzumab and hyaluronidase-oysk) in the government-authorized prescribing documentation.

Documented Overdose Information

Governmental safety labeling for Hylosept explicitly states that No information on overdosage is available. This means that there are no formal, documented reports, specific symptoms, or recommended treatment protocols for an overdose listed in the official regulatory sections.

Since the drug is administered by a healthcare professional in a controlled clinical setting, an accidental overdosage is considered unlikely to occur. Given the absence of specific overdose guidance, any suspected over-exposure would be managed by general medical supportive care.

When to Seek Emergency Medical Help

Immediate emergency medical attention is required if any severe or unexpected signs of toxicity occur following the drug's administration. While not classified as specific overdose symptoms, potential severe adverse events described in the regulatory documents that warrant immediate help include:

  • Signs of serious cardiac toxicity (e.g., severe shortness of breath, new or worsening cough, swelling of the legs).
  • Signs of serious pulmonary toxicity (e.g., severe difficulty breathing or signs of fluid in the lungs).
  • A severe infusion- or administration-related reaction (e.g., anaphylaxis, severe rash, wheezing, or low blood pressure).

If a suspected overdose or severe reaction occurs, contact a healthcare professional or an emergency medical services provider immediately.

Therapeutic Uses of Hylosept

Hylosept is commonly used to help manage conditions presenting with systemic or localized discomfort that are associated with acute or disruptive episodes.

The medication is generally applied in addressing symptoms that interfere with daily functioning, commonly used across conditions presenting with acute episodes that produce localized distress. This includes managing conditions characterized by periods of heightened symptoms, such as acute irritative states of the skin or symptoms linked to organ-specific functional stress like those seen in bacterial conjunctivitis. It is often used during phases when symptoms become more noticeable, particularly in conditions where the inflammatory or irritative states are exacerbated.

In these uses, Hylosept offers symptomatic relief that helps patients cope more steadily and supports general well-being during symptomatic phases. Furthermore, in its systemic use, it is relevant in contexts involving heightened systemic burden, applied across therapeutic areas involving significant symptom expression, assisting with maintaining functional stability.

Quick Fact: Relief for Localized Inflammatory Symptoms

Eligibility and Restrictions for Use

This information is derived strictly from official government regulatory documents (e.g., Summary of Product Characteristics) for the active substance, fusidic acid, and describes official eligibility and non-eligibility rules.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Most adults and children are generally eligible for topical use.
Populations for whom use is contraindicated Individuals with known hypersensitivity to fusidic acid, sodium fusidate, or any of the product's excipients must not use the medicine.
Age-related eligibility rules Children and Adults are generally eligible. Use on infants and application over large areas require caution due to the potential for increased systemic absorption.
Pregnancy and lactation eligibility status Can be used during both pregnancy and breastfeeding as systemic exposure from topical application is considered negligible. Women who are breastfeeding are advised to avoid applying the cream directly to the breasts.
Eligibility-related restrictions Use near the eyes should be avoided. The medicine should not be used for infections caused by organisms known to be non-susceptible to fusidic acid.

Resulting Eligibility Structure

Official regulatory documents establish an absolute contraindication based on allergic status. All other limitations are defined as conditional restrictions, meaning use is generally permitted across most life stages, including in pregnant and breastfeeding women, provided specific rules on the method or location of application are followed to limit risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hylosept has the potential for pharmacodynamic interactions due to the risk of hypokalaemia (low potassium levels in the blood), especially with long-term use. This electrolyte imbalance is the primary documented mechanism by which interactions occur.

Clinically Significant Interactions

Interacting Product Category Mechanism and Potential Effect
Cardiac Glycosides (e.g., Digoxin) Hypokalaemia potentiates the effects of these medicines, significantly increasing the risk of toxicity and adverse cardiac events.
Antiarrhythmic Drugs and Drugs that induce reversion to sinus rhythm (e.g., Quinidine) The reduction of serum potassium levels interferes with the proper action of these heart rhythm medications.
Other Hypokalaemia-Inducing Drugs (e.g., Thiazide Diuretics, Adrenocorticosteroids, Liquorice Root) Concomitant use with these products may aggravate the electrolyte imbalance, leading to more severe or rapid potassium depletion.

All patients should inform their healthcare provider of all other medicines, herbal products, and supplements being taken to assess the risk of developing hypokalaemia and related complications. The documented interaction structure focuses solely on the critical impact of electrolyte imbalance on cardiac and diuretic therapies.

Mechanism of Action

Fusidic Acid exerts a highly specific bacteriostatic effect by interfering with protein synthesis in susceptible bacteria. The drug acts as a specialized inhibitor of Elongation Factor G (EF-G), an essential enzyme for bacterial growth. The molecule binds to and stabilizes the complex formed by EF-G and the bacterial ribosome, preventing the enzyme from detaching after completing its translocation step. This targeted binding acts as a physical lock, immediately halting the ribosomal machinery. By trapping EF-G, the drug ensures that the ribosome cannot progress along the messenger RNA (mRNA) or be recycled for subsequent protein synthesis cycles. This molecular stall prevents the addition of new amino acids to the polypeptide chain, resulting in the cessation of essential protein production required for cell division and maintenance. The physiological consequence is suppressed bacterial proliferation. The function of this mechanism is constrained by acquired bacterial resistance, primarily through a chromosomal mutation in the fusA gene, which changes the EF-G binding site, or the presence of proteins (like FusB) that can override the drug's stabilization, resulting in the loss of inhibitory action.

Dosage and Administration Information

How to Use Hylosept (Fusidic Acid 20 mg/g)

This section outlines the instructions for the proper use of Hylosept (Fusidic Acid 20 mg/g) cream or ointment. These instructions must be followed precisely.

Administration and Dosage

Area of Instruction Labeled Guideline
Route Cutaneous use (topical application only). Do not ingest or use in the eyes.
Dosage Form Available as a Cream or Ointment, both typically 20 mg/g.
Standard Dose Apply a small amount gently to the affected skin area.

Frequency and Duration

Application Context Recommended Frequency
Uncovered Lesions Apply three or four times daily.
Covered Lesions (Under dressing/bandage) Less frequent application may be sufficient, such as once or twice daily.

The typical duration of treatment is 1 to 2 weeks, or as specifically directed by a healthcare provider. Do not use for longer than the recommended period.

Procedural Instructions

  1. Hand Hygiene: Wash hands thoroughly before and after applying the cream or ointment (unless the hands are the area being treated).
  2. Application: Gently rub the small amount of product into the affected skin area.
  3. Special Care: Avoid contact with the eyes and mucous membranes during application.

Missed Dose

If a dose is missed, apply the cream or ointment as soon as it is remembered, then continue with the regular schedule. Do not apply a double amount to compensate for a missed application.

Recent Clinical Evidence

Research evidence / Overview of Studies for Hylosept

Evidence for Localized Skin and Ocular Infections (Topical Use)

Research related to Hylosept's study in conditions characterized by localized irritative states of the skin, such as impetigo, has included Randomized Controlled Trials (RCTs). These studies primarily tracked clinical and bacteriological endpoints in adults and children, measuring observable changes in lesion severity and the bacterial population. Similarly, controlled ophthalmic trials explored its application in conditions involving heightened ocular symptoms, such as acute bacterial conjunctivitis, tracking symptomatic changes over short-term intervals (around seven days). Across both topical and ocular uses, findings are often limited to the defined time intervals of the trial, and the long-term perspective may be considered uncertain.

Evidence for Systemic and Chronic Internal Infections

The research base for using Hylosept in conditions presenting with heightened systemic burden, such as serious bone and joint infections or bacteremia, consists of studies with varied designs and outcomes. This evidence base includes older observational data and case series, rather than large comparative RCTs. Studies examined long-term data for adults with severe staphylococcal infections, particularly when the medicine was used in combination regimens. Because the evidence quality varies across these studies, certainty remains low for modern, controlled comparisons, and the availability of updated data is limited.

Research Gaps and Special Populations

While research has explored the medicine's application in pediatric groups for topical and ocular use, data for certain groups remain insufficient. Comparative evidence is lacking for large cohorts of older adults, and there is limited information for patients with significant comorbidities. Overall, research is concentrated on short-term outcomes. The risk of antimicrobial resistance when the medicine is used alone, and the durability of any observed patterns, remain significant areas of scientific uncertainty.

Frequently Asked Questions (FAQ)

Common questions about Hylosept (FAQ)

Q: Does it make you sleepy?

A: Yes, official regulatory information indicates that side effects like drowsiness and somnolence (a medical term for sleepiness) are common or very common with Hylosept. Due to these potential effects, the product label includes warnings that activities requiring mental alertness, such as operating heavy machinery or driving, may be impaired. This safety information is based on data found in regulatory documents.

Q: Can children 2 years old use it?

A: The official product information for Hylosept does not list an authorization for use in children as young as 2 years old. Regulatory bodies, such as Health Canada, have stated that the safety and effectiveness of this medicine have not been established for use in this pediatric age group. Because of this, the medication is not indicated for the treatment of patients under the authorized age limit.

How should Hylosept be stored and disposed of?

The storage and disposal of Hylosept (Fusidic Acid) must strictly follow the conditions specified in official regulatory labeling to ensure product stability and safe handling.

Official Storage Requirements

Element Mandatory Condition
Temperature Store below 25°C (77°F); Keep from freezing.
Protection Protect from light and moisture.
Container Keep in the original container, tightly closed.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

In-use stability requires that unused eye drops or cream be discarded 28 days (or 4 weeks) after first opening the container. Disposal of unused or expired Hylosept must be done according to local requirements, and the product must not be thrown away via wastewater or household waste, as specified by governmental environmental guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPoland

Equivalent of Hylosept found in:

A-Z Index: